FCCC LOGO Faculty Publications
Brown PA , Shah B , Fathi A , Wieduwilt M , Advani A , Aoun P , Barta SK , Boyer MW , Bryan T , Burke PW , Cassaday R , Coccia PF , Coutre SE , Damon LE , DeAngelo DJ , Frankfurt O , Greer JP , Kantarjian HM , Klisovic RB , Kupfer G , Litzow M , Liu A , Mattison R , Park J , Rubnitz J , Saad A , Uy GL , Wang ES , Gregory KM , Ogba N
NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017
J Natl Compr Canc Netw. 2017 Sep;15(9) :1091-1102
PMID: 28874594   
Back to previous list
The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, the management of relapsed or refractory (R/R) ALL remains challenging and prognosis is poor. The NCCN Guidelines for ALL provide recommendations on standard treatment approaches based on current evidence. These NCCN Guidelines Insights summarize treatment recommendations for R/R ALL and highlight important updates, and provide a summary of the panel's discussion and underlying data supporting the most recent recommendations for R/R ALL management.
1540-1413 Brown, Patrick A Shah, Bijal Fathi, Amir Wieduwilt, Matthew Advani, Anjali Aoun, Patricia Barta, Stefan K Boyer, Michael W Bryan, Teresa Burke, Patrick W Cassaday, Ryan Coccia, Peter F Coutre, Steven E Damon, Lloyd E DeAngelo, Daniel J Frankfurt, Olga Greer, John P Kantarjian, Hagop M Klisovic, Rebecca B Kupfer, Gary Litzow, Mark Liu, Arthur Mattison, Ryan Park, Jae Rubnitz, Jeffrey Saad, Ayman Uy, Geoffrey L Wang, Eunice S Gregory, Kristina M Ogba, Ndiya Journal Article United States J Natl Compr Canc Netw. 2017 Sep;15(9):1091-1102. doi: 10.6004/jnccn.2017.0147.